Intravenous Immunoglobulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Intravenous Immunoglobulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The intravenous immunoglobulin market is expected to register a CAGR of 7.13% over the forecast period, 2022-2027.

The outbreak of the COVID-19 pandemic, in its latter phase, is likely to positively impact the intravenous immunoglobulin market's growth. According to an article titled "COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience" published in December 2020, the study revealed that out of 100 individuals with primary immunodeficiency (PID), symptomatic secondary immunodeficiency (SID), autoinflammatory diseases, and C1 inhibitor deficiency, 70% of the individuals were infected with the SARS-CoV-2 virus, and 59% were admitted to hospitals, with 8% being admitted to intensive care units. Thus, immune-deficient individuals are at a higher risk of being infected with COVID-19, so the market for intravenous immunoglobulin therapies is expected to grow during the pandemic. Additionally, as per an October 2020 published article titled, "The use of Intravenous Immunoglobulin Gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial," the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to improve the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Thus, the studied market is expected to witness healthy growth during the pandemic due to the above factors.

Further, the significant factors fueling the market's growth are the rise in the geriatric population, the increase in the adoption of immunoglobulin treatment, and the growing prevalence of immunodeficiency diseases and bleeding disorders.

The increasing adoption of immunoglobulin with product launches and approvals is likely to boost the market's growth in the future. For instance, in June 2022, Amgen received United States Food and Drug Administration (FDA) approval for RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Additionally, in December 2021, the United States Food and Drug Administration approved Vyvgart (efgartigimod) to Argenx BV for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody. Thus, the market is expected to witness significant growth over the forecast period due to the abovementioned factors. However, stringent government regulations and the high cost of therapy may hinder the growth of the market.

Key Market TrendsThe Primary Immunodeficiency Diseases Segment is Expected to Register a High CAGR Over the Forecast Period

By application, the primary immunodeficiency disease (PIDs) segment is expected to hold a significant market share.

Intravenous immunoglobulin (IVIG) therapy has been majorly used in treating primary immunodeficiency diseases (PIDs) and other immune deficiency disorders over the past few years. There are several specific medical therapies available for people with PIDs with antibody deficiency, which account for more than half of the primary immunodeficiencies. These illnesses, such as common variable immune deficiency (CVID), X-linked agammaglobulinemia (XLA), and other disorders, are characterized by a lack of and/or impaired antibody function. The high burden of primary immunodeficiency is a major factor fueling the segment's growth. For instance, as per the research article titled "Systematic Review of Primary Immunodeficiency Diseases in Malaysia: 1979–2020", published in Frontiers in Immunology in August 2020, approximately six million people are predicted to be living with PIDs globally, among which only 27,000–60,000 cases have been diagnosed. As per the above-mentioned source, the incidence of PIDs in Singapore was observed to be 2.65 per 100,000 live births, with an estimated occurrence rate of one in 37,000 live births. Also, as per an April 2020 update by the Centers for Disease Control and Prevention (CDC), there are more than 400 types of primary immunodeficiencies that vary in severity. Thus, these statistics reflect the rising need for immunoglobulins for the treatment of immunodeficiency disorders. Hence, the growing burden of PIDs globally is expected to drive the studied segment’s growth over the forecast period.

Furthermore, several pharmaceutical companies are engaged in developing immunoglobulin products for the treatment of primary immunodeficiency. For instance, in May 2021, GC Pharma reported that the United States Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) for "GC5107 (Immune Globulin Intravenous (Human), 10% Liquid)" intended for the treatment of Primary Humoral Immunodeficiency, a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system.

Hence, with the availability of IVIG therapies and the advancements in intravenous immunoglobulin products to treat the highly prevalent primary immunodeficiency diseases, the studied segment is expected to grow significantly over the coming years.

North America is Expected to Dominate the Market Over The Forecast Period

The United States is expected to hold a major share of the market in North America. The major factors propelling the market's growth in the country are a developed and well-structured healthcare system; a growing focus on research and development; and the strong presence of market players.

Additionally, the growing burden of target diseases such as primary immunodeficiency diseases in the region is expected to boost the market's growth. For instance, according to the National Institute of Allergy and Infectious Diseases, in 2020, more than 400 types of varied PIDs were diagnosed in the United States, accounting for more than 500,000 American populations affected by PIDs. Additionally, as per the USIDNET Registry, 2020, the frequency of severe combined immunodeficiency (SCID) in the American population was 355. Further, the increasing research and development activities and the rapid product approvals are predicted to drive the intravenous immunoglobulin market growth in the region.

Furthermore, in August 2021, Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company based in the United States, reported the start of Phase III clinical trial to evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous (COVID-HIG) plasma-derived therapy as a potential outpatient treatment for patients with coronavirus (COVID-19) who are at high risk of progression to severe disease.

Additionally, in February 2021, Pfizer received United States Food and Drug Administration approval for the supplemental Biologics License Application (sBLA), which was submitted for PANZYGA, an intravenous immunoglobulin (IVIg) to treat adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.

Competitive Landscape

The intravenous immunoglobulin market is moderately competitive, and vital global players manufacture most of the intravenous immunoglobulin therapies. Market leaders with more funds for research and a better distribution system have established their positions in the market. The key players in the studied market are Grifols SA, Takeda Pharmaceutical Company Limited, Biotest AG, Bio Products Laboratory Limited, and Kedrion SpA, among others. The major players are involved in strategies such as acquisitions, collaborations, and new product launches to secure their positions in the global market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.